In Brief: Vasomedical Inc.
This article was originally published in The Gray Sheet
Executive Summary
Vasomedical Inc.: Results of a 50-patient study of Enhanced External Counterpulsation (EECP) technology -- "a non-surgical therapy intended to reduce or eliminate symptoms of patients suffering from chronic stable angina pectoris" -- show that all patients receiving the treatment reported a decrease in anginal symptoms, researchers report in the May issue of The American Journal of Cardiology. Investigators William Lawson, MD, et. al., State University of New York at Stony Brook, say EECP facilitates blood flow through coronary collatorals by aiding the development of new collatorals or by enhancing flow through existing collatorals. The study also reports that 95% of patients with blockage of one vessel, 90% of patients with dual vessel blockage and 43% with triple blockage, experienced improvement post-treatment...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.